ZA200105548B - Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use. - Google Patents
Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use. Download PDFInfo
- Publication number
- ZA200105548B ZA200105548B ZA200105548A ZA200105548A ZA200105548B ZA 200105548 B ZA200105548 B ZA 200105548B ZA 200105548 A ZA200105548 A ZA 200105548A ZA 200105548 A ZA200105548 A ZA 200105548A ZA 200105548 B ZA200105548 B ZA 200105548B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzodioxan
- alkyl
- piperazine
- ethyl
- phenyl
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title claims description 28
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000004885 piperazines Chemical class 0.000 title claims description 5
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 56
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 39
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- -1 -SH Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 230000000697 serotonin reuptake Effects 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000019022 Mood disease Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 5
- 208000028017 Psychotic disease Diseases 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- 230000008485 antagonism Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- RCQDOGSVNHWIMN-UHFFFAOYSA-N 1-[2-(7-chloro-1-benzofuran-3-yl)ethyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCC1=COC2=C1C=CC=C2Cl RCQDOGSVNHWIMN-UHFFFAOYSA-N 0.000 claims description 3
- JTPLNPHPNIYCDU-UHFFFAOYSA-N 1-[2-(1-benzofuran-3-yl)ethyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCC1=COC2=CC=CC=C12 JTPLNPHPNIYCDU-UHFFFAOYSA-N 0.000 claims description 2
- CLJAOJUFOSBCLF-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-[2-(5-fluoro-1-benzofuran-3-yl)ethyl]-3,6-dihydro-2h-pyridine Chemical compound O1CCOC2=C1C=CC=C2C(CC1)=CCN1CCC1=COC2=CC=C(F)C=C21 CLJAOJUFOSBCLF-UHFFFAOYSA-N 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 8
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- AOQLMFXQYMGEAC-UHFFFAOYSA-N 1-[2-(5-chloro-1-benzofuran-3-yl)ethyl]-4-(2,3-dihydro-1-benzofuran-7-yl)-3,6-dihydro-2h-pyridine Chemical compound C12=CC(Cl)=CC=C2OC=C1CCN(CC=1)CCC=1C1=CC=CC2=C1OCC2 AOQLMFXQYMGEAC-UHFFFAOYSA-N 0.000 claims 1
- VOCJZUCWJMDWKK-UHFFFAOYSA-N 1-[3-(4-chloro-1-benzofuran-3-yl)propyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[4-(4-methyl-1-benzofuran-3-yl)butyl]piperazine Chemical compound O1CCOC2=C1C=CC=C2N2CCN(CC2)CCCCC2=COC1=C2C(=CC=C1)C.O1CCOC2=C1C=CC=C2N2CCN(CC2)CCCC2=COC1=C2C(=CC=C1)Cl VOCJZUCWJMDWKK-UHFFFAOYSA-N 0.000 claims 1
- SUQYMRDMSUAURX-UHFFFAOYSA-N 1-[3-(7-chloro-4-methyl-1-benzofuran-3-yl)propyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCCC1=COC2=C1C(C)=CC=C2Cl SUQYMRDMSUAURX-UHFFFAOYSA-N 0.000 claims 1
- GMDWUJFAFNMEJC-UHFFFAOYSA-N 3-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-6-fluoro-1,2-benzoxazole Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCCC1=NOC2=CC(F)=CC=C21 GMDWUJFAFNMEJC-UHFFFAOYSA-N 0.000 claims 1
- OPUKZZXGORALBS-UHFFFAOYSA-N 5-[4-[3-(7-chloro-1-benzofuran-3-yl)propyl]piperazin-1-yl]-2,3-dihydro-1,4-benzodioxine-8-carbonitrile Chemical compound O1CCOC2=C1C(C#N)=CC=C2N(CC1)CCN1CCCC1=COC2=C1C=CC=C2Cl OPUKZZXGORALBS-UHFFFAOYSA-N 0.000 claims 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000020401 Depressive disease Diseases 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000010304 firing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 210000002348 5-ht neuron Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000002152 alkylating effect Effects 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 3
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- YHRGALLCZYXYAO-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-2,3-dihydro-1,4-benzodioxine-2-carbonitrile Chemical compound O1C(C#N)COC2=C1C=CC=C2N(CC1)CCC1CCC1=CNC2=CC(Cl)=CC=C21 YHRGALLCZYXYAO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LQKDRSKMMGTYOZ-UHFFFAOYSA-N [5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-2,3-dihydro-1,4-benzodioxin-2-yl]methanol Chemical compound ClC1=CC=C2C(CCC3CCN(CC3)C3=CC=CC4=C3OCC(O4)CO)=CNC2=C1 LQKDRSKMMGTYOZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 229940053544 other antidepressants in atc Drugs 0.000 description 2
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- SRRHGXBUMJYAHD-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[2-(4-methyl-1-benzofuran-3-yl)ethyl]piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCC1=COC2=C1C(C)=CC=C2 SRRHGXBUMJYAHD-UHFFFAOYSA-N 0.000 description 1
- OGQCMEYPNLMMSX-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[4-(4-methyl-1-benzofuran-3-yl)butyl]piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCCCC1=COC2=C1C(C)=CC=C2 OGQCMEYPNLMMSX-UHFFFAOYSA-N 0.000 description 1
- AJSQIMXPQKUZAF-UHFFFAOYSA-N 1-[4-(4-chloro-1-benzofuran-3-yl)butyl]-4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine Chemical compound O1CCOC2=C1C=CC=C2N(CC1)CCN1CCCCC1=COC2=C1C(Cl)=CC=C2 AJSQIMXPQKUZAF-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- UODUNHOUWMKBOH-UHFFFAOYSA-N 4-(1-benzofuran-7-yl)-1-[2-(5-fluoro-1-benzofuran-3-yl)ethyl]-3,6-dihydro-2h-pyridine Chemical compound C12=CC(F)=CC=C2OC=C1CCN(CC=1)CCC=1C1=CC=CC2=C1OC=C2 UODUNHOUWMKBOH-UHFFFAOYSA-N 0.000 description 1
- JWBSGKFBCRXIMF-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperazin-1-yl]-2,3-dihydro-1,4-benzodioxine-2-carbonitrile Chemical compound O1C(C#N)COC2=C1C=CC=C2N(CC1)CCN1CCC1=CNC2=CC(Cl)=CC=C21 JWBSGKFBCRXIMF-UHFFFAOYSA-N 0.000 description 1
- ADIMEGSDJPRBGN-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-2,3-dihydro-1,4-benzodioxin-2-amine Chemical compound ClC1=CC=C2C(CCC3CCN(CC3)C3=CC=CC4=C3OCC(O4)N)=CNC2=C1 ADIMEGSDJPRBGN-UHFFFAOYSA-N 0.000 description 1
- SDNTVOZIBAGTRA-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-3h-1,4-benzodioxine-2,2-dicarbonitrile Chemical compound O1C(C#N)(C#N)COC2=C1C=CC=C2N(CC1)CCC1CCC1=CNC2=CC(Cl)=CC=C21 SDNTVOZIBAGTRA-UHFFFAOYSA-N 0.000 description 1
- HWMUOPWCCNNPIL-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-n,n-dimethyl-2,3-dihydro-1,4-benzodioxin-2-amine Chemical compound ClC1=CC=C2C(CCC3CCN(CC3)C3=CC=CC4=C3OCC(O4)N(C)C)=CNC2=C1 HWMUOPWCCNNPIL-UHFFFAOYSA-N 0.000 description 1
- WHMHMCFFTSCHKX-UHFFFAOYSA-N 5-[4-[2-(6-chloro-1h-indol-3-yl)ethyl]piperidin-1-yl]-n,n-dimethyl-2,3-dihydro-1,4-benzodioxine-2-carboxamide Chemical compound ClC1=CC=C2C(CCC3CCN(CC3)C3=CC=CC4=C3OCC(O4)C(=O)N(C)C)=CNC2=C1 WHMHMCFFTSCHKX-UHFFFAOYSA-N 0.000 description 1
- GCSZUESTMZEVPG-UHFFFAOYSA-N 6-chloro-3-[2-[1-[2-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperidin-4-yl]ethyl]-1h-indole Chemical compound ClC1=CC=C2C(CCC3CCN(CC3)C3=CC=CC4=C3OCC(O4)C(F)(F)F)=CNC2=C1 GCSZUESTMZEVPG-UHFFFAOYSA-N 0.000 description 1
- KWZDQWBBJCCVAE-UHFFFAOYSA-N 6-chloro-3-[2-[4-[2-(trifluoromethyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperazin-1-yl]ethyl]-1h-indole Chemical compound ClC1=CC=C2C(CCN3CCN(CC3)C3=CC=CC4=C3OCC(O4)C(F)(F)F)=CNC2=C1 KWZDQWBBJCCVAE-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical class C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001966 cerebroprotective effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900084 | 1999-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105548B true ZA200105548B (en) | 2002-07-05 |
Family
ID=8089560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105548A ZA200105548B (en) | 1999-01-22 | 2001-07-05 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6596722B2 (hu) |
| EP (1) | EP1149087B1 (hu) |
| JP (1) | JP2002535322A (hu) |
| KR (1) | KR20010101606A (hu) |
| CN (1) | CN1344265A (hu) |
| AR (1) | AR022303A1 (hu) |
| AT (1) | ATE263763T1 (hu) |
| AU (1) | AU767377B2 (hu) |
| BG (1) | BG105781A (hu) |
| BR (1) | BR0009007A (hu) |
| CA (1) | CA2361059A1 (hu) |
| CZ (1) | CZ20012657A3 (hu) |
| DE (1) | DE60009663T2 (hu) |
| EA (1) | EA200100798A1 (hu) |
| HK (1) | HK1045505A1 (hu) |
| HU (1) | HUP0105065A3 (hu) |
| IL (1) | IL144113A0 (hu) |
| IS (1) | IS5983A (hu) |
| MX (1) | MXPA01007226A (hu) |
| NO (1) | NO20013538L (hu) |
| NZ (1) | NZ512732A (hu) |
| PL (1) | PL349909A1 (hu) |
| SK (1) | SK10302001A3 (hu) |
| TR (1) | TR200102089T2 (hu) |
| WO (1) | WO2000043382A1 (hu) |
| ZA (1) | ZA200105548B (hu) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ295937B6 (cs) * | 1997-07-25 | 2005-12-14 | H. Lundbeck A/S | Indolové nebo 2,3-dihydroindolové deriváty |
| BR0013498A (pt) * | 1999-08-23 | 2002-05-14 | Solvay Pharm Bv | Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc |
| AR027133A1 (es) * | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
| ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| EP1425029A4 (en) | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US7153858B2 (en) * | 2003-01-31 | 2006-12-26 | Epix Delaware, Inc. | Arylpiperazinyl compounds |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7235569B2 (en) | 2003-05-02 | 2007-06-26 | Wyeth | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use |
| US7276603B2 (en) | 2003-05-02 | 2007-10-02 | Wyeth | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US20060122175A1 (en) * | 2004-12-07 | 2006-06-08 | Solvay Pharmaceuticals B.V. | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| US7371769B2 (en) | 2004-12-07 | 2008-05-13 | Solvay Pharmaceuticals B.V. | Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites |
| US20070072870A2 (en) | 2004-12-08 | 2007-03-29 | Solvay Pharmeceuticals B.V. | Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| PL1824479T3 (pl) * | 2004-12-08 | 2009-04-30 | Solvay Pharm Bv | Pochodne fenylopiperazyny o połączonym działaniu częściowego agonisty receptora dopaminowego D2 i hamowania wychwytu zwrotnego serotoniny |
| DE102004063797A1 (de) * | 2004-12-30 | 2006-07-13 | Schwarz Pharma Ag | Sauerstoffhaltige annelierte Phenylpiperazin- und Phenyldiazepancarboxamide |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| KR100589877B1 (ko) * | 2005-12-20 | 2006-06-19 | 주식회사 픽슨이앤씨 | 파형강판 구조물의 보강라이너 설치용 거푸집 |
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) * | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| RU2519123C2 (ru) | 2009-07-06 | 2014-06-10 | Аэрпио Терапьютикс Инк. | Соединения, композиции и способы предупреждения метастазов раковых клеток |
| JP5847194B2 (ja) | 2010-12-20 | 2016-01-20 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | ２−カルボキサミド−４−ピペラジニル−ベンゾフラン誘導体 |
| CN104039351A (zh) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | 用于治疗血管渗漏综合征和癌症的方法 |
| CN104337812B (zh) | 2013-07-29 | 2018-09-14 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其使用方法和用途 |
| CN104725363B (zh) * | 2013-12-20 | 2019-03-01 | 广东东阳光药业有限公司 | 取代的哌嗪化合物及其使用方法和用途 |
| WO2016192657A1 (en) * | 2015-06-03 | 2016-12-08 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use and use thereof |
| TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Ｇｌｐ－１受體促效劑及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| FR2670491B1 (fr) * | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| RU2124511C1 (ru) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Производные пиперазина |
| RU2118322C1 (ru) * | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
-
2000
- 2000-01-17 AR ARP000100197A patent/AR022303A1/es not_active Application Discontinuation
- 2000-01-21 CN CN00805148A patent/CN1344265A/zh active Pending
- 2000-01-21 MX MXPA01007226A patent/MXPA01007226A/es not_active Application Discontinuation
- 2000-01-21 AT AT00901481T patent/ATE263763T1/de not_active IP Right Cessation
- 2000-01-21 EA EA200100798A patent/EA200100798A1/ru unknown
- 2000-01-21 BR BR0009007-7A patent/BR0009007A/pt not_active IP Right Cessation
- 2000-01-21 AU AU22781/00A patent/AU767377B2/en not_active Ceased
- 2000-01-21 KR KR1020017009122A patent/KR20010101606A/ko not_active Application Discontinuation
- 2000-01-21 IL IL14411300A patent/IL144113A0/xx unknown
- 2000-01-21 DE DE60009663T patent/DE60009663T2/de not_active Expired - Fee Related
- 2000-01-21 CA CA002361059A patent/CA2361059A1/en not_active Abandoned
- 2000-01-21 JP JP2000594798A patent/JP2002535322A/ja not_active Withdrawn
- 2000-01-21 CZ CZ20012657A patent/CZ20012657A3/cs unknown
- 2000-01-21 SK SK1030-2001A patent/SK10302001A3/sk unknown
- 2000-01-21 HU HU0105065A patent/HUP0105065A3/hu unknown
- 2000-01-21 EP EP00901481A patent/EP1149087B1/en not_active Expired - Lifetime
- 2000-01-21 NZ NZ512732A patent/NZ512732A/en unknown
- 2000-01-21 TR TR2001/02089T patent/TR200102089T2/xx unknown
- 2000-01-21 WO PCT/DK2000/000026 patent/WO2000043382A1/en not_active Application Discontinuation
- 2000-01-21 PL PL00349909A patent/PL349909A1/xx not_active Application Discontinuation
-
2001
- 2001-06-28 IS IS5983A patent/IS5983A/is unknown
- 2001-07-05 ZA ZA200105548A patent/ZA200105548B/en unknown
- 2001-07-09 US US09/901,585 patent/US6596722B2/en not_active Expired - Fee Related
- 2001-07-17 NO NO20013538A patent/NO20013538L/no not_active Application Discontinuation
- 2001-08-03 BG BG105781A patent/BG105781A/xx unknown
-
2002
- 2002-05-16 US US10/147,950 patent/US20020173512A1/en not_active Abandoned
- 2002-09-20 HK HK02106884.4A patent/HK1045505A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1344265A (zh) | 2002-04-10 |
| EA200100798A1 (ru) | 2001-12-24 |
| NO20013538D0 (no) | 2001-07-17 |
| CZ20012657A3 (cs) | 2002-02-13 |
| MXPA01007226A (es) | 2002-04-24 |
| DE60009663T2 (de) | 2005-04-14 |
| HUP0105065A2 (hu) | 2002-07-29 |
| AU2278100A (en) | 2000-08-07 |
| AR022303A1 (es) | 2002-09-04 |
| TR200102089T2 (tr) | 2002-07-22 |
| IS5983A (is) | 2001-06-28 |
| US20020173512A1 (en) | 2002-11-21 |
| EP1149087B1 (en) | 2004-04-07 |
| US6596722B2 (en) | 2003-07-22 |
| AU767377B2 (en) | 2003-11-06 |
| HK1045505A1 (zh) | 2002-11-29 |
| US20020035113A1 (en) | 2002-03-21 |
| PL349909A1 (en) | 2002-10-07 |
| BG105781A (en) | 2002-05-31 |
| SK10302001A3 (sk) | 2002-01-07 |
| CA2361059A1 (en) | 2000-07-27 |
| EP1149087A1 (en) | 2001-10-31 |
| KR20010101606A (ko) | 2001-11-14 |
| NZ512732A (en) | 2003-10-31 |
| WO2000043382A1 (en) | 2000-07-27 |
| DE60009663D1 (de) | 2004-05-13 |
| NO20013538L (no) | 2001-09-17 |
| HUP0105065A3 (en) | 2003-06-30 |
| IL144113A0 (en) | 2002-05-23 |
| JP2002535322A (ja) | 2002-10-22 |
| ATE263763T1 (de) | 2004-04-15 |
| BR0009007A (pt) | 2001-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200105548B (en) | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use. | |
| AU736596B2 (en) | Indole and 2,3-dihydroindole derivatives, their preparation and use | |
| US20020107254A1 (en) | Serotonergic agents | |
| CZ111496A3 (en) | Novel (r)-5-carbamoyl-8-fluoro-3-n-n-disubstituted amino-3,4-dihydro-2h-1-benzopyranes | |
| BG63083B1 (bg) | Заместени тетрациклични тетрахидрофуранови производни | |
| JP2001515899A (ja) | テトラヒドロガンマ−カルボリン類 | |
| CA2567483A1 (en) | Pyrazinylmethyl lactam derivatives | |
| HU224312B1 (hu) | 2-Amino-indán-származékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| JP2008503559A (ja) | Ｃｎｓ障害を治療するためのピリジルピペラジン | |
| WO2004099214A1 (en) | Quinoline 3-amino chroman derivatives | |
| JP3095533B2 (ja) | 抗精神病剤用ベンゾジオキサン誘導体 | |
| US7816362B2 (en) | Serotonergic agents | |
| TW201309708A (zh) | 新穎二氫－□唑并苯并二氮雜□酮化合物、其製備方法及含其之醫藥組合物 | |
| Kakefuda et al. | Synthesis and pharmacological evaluation of 2-(3-Piperidyl)-1, 2, 3, 4-tetrahydroisoquinoline derivatives as specific bradycardic agents | |
| SK284866B6 (sk) | Indolové alebo 2,3-dihydroindolové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie | |
| JP2002543071A (ja) | うつ病治療用のテトラヒドロイソキノリニルインドール誘導体 |